Bhui A, Bureau J, Abbas A, Mondal A, Scherrer K, Kurkure A, Therwath A
UNIV PARIS 07,ONCOL MOL LAB,F-75005 PARIS,FRANCE. FAC MED NIMES,LAB BIOL CELLULAIRE & IMMUNOGENET,NIMES,FRANCE. CNRS,INST JACQUES MONOD,LAB BIOCHIM DIFFERENTIAT,PARIS,FRANCE. UNIV PARIS 07,F-75005 PARIS,FRANCE. BREACH CANDY HOSP & RES CTR,BOMBAY 400026,MAHARASHTRA,INDIA.
Int J Oncol. 1996 Oct;9(4):669-77. doi: 10.3892/ijo.9.4.669.
Epidemiological studies have revealed that Parsi women have a higher incidence of breast cancer than non-Parsis and that they are more susceptible to breast cancer. We have studied the cellular distribution of two prosomal proteins p23K in parallel to the p30.33K and proliferation marker Ki-67 as potential markers to identify high risk population for breast cancers. Flow cytometry data demonstrated that the Parsi benign and non-Parsi malignants have a higher number of cells labelled with these two prosomal protein antibodies than the non-Parsi benign and European 'normals'. Using immunohistochemical methods, p23 K was found to be significantly higher in Parsi and non-Parsi malignants as well as in non-Parsi benigns. In our FCM analysis, intergroup comparison showed, interestingly, a significantly higher expression of both p23K and p30.33K in Parsi benigns as compared to non-Parsis, raising the possibility that benign tumors of Parsis represent already premalignant lesions. The present study, in addition, proposes the prosomal antigens as likely cell proliferation markers comparable to Ki-67.
流行病学研究表明,帕西族女性患乳腺癌的几率高于非帕西族女性,且她们对乳腺癌更易感。我们研究了两种前体蛋白p23K与p30.33K的细胞分布情况,并将其与增殖标志物Ki-67作为识别乳腺癌高危人群的潜在标志物进行了平行研究。流式细胞术数据表明,与非帕西族良性组织和欧洲“正常”组织相比,帕西族良性组织和非帕西族恶性组织中被这两种前体蛋白抗体标记的细胞数量更多。采用免疫组化方法发现,p23K在帕西族和非帕西族恶性组织以及非帕西族良性组织中均显著升高。在我们的流式细胞术分析中,组间比较有趣地显示,与非帕西族相比,帕西族良性组织中p23K和p30.33K的表达均显著更高,这增加了帕西族良性肿瘤已代表癌前病变的可能性。此外,本研究提出前体抗原可能是与Ki-67相当的细胞增殖标志物。